More tools:Markets·Screener·Research·Chat

IN8bio, Inc. Common Stock (INAB) Financial Statements

IN8bio, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00XX9K2G7
XNAS · usd
1.10▼ 0.04 (-3.51%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.14
Day's Range1.13 – 1.20
52-Week Range0.88 – 2.73
Volume31.4K
Avg Volume66.2K
Share Statistics
Shares Outstanding
Employees17
ExchangeXNAS
Listed2021-07-30
Share count as of August 3, 2026
Loading Income Statement…
Key questions about IN8bio, Inc. Common Stock (INAB)
What is IN8bio, Inc. Common Stock's Market Cap?
IN8bio, Inc. Common Stock's Market Cap is $10.8M, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's Enterprise Value?
IN8bio, Inc. Common Stock's Enterprise Value is -$7.2M, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's EV / EBITDA?
IN8bio, Inc. Common Stock's EV / EBITDA is 0.4×, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's Net Income (TTM)?
IN8bio, Inc. Common Stock's Net Income (TTM) is -$18.7M, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's EBITDA?
IN8bio, Inc. Common Stock's EBITDA is -$17.7M, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's Diluted EPS (TTM)?
IN8bio, Inc. Common Stock's Diluted EPS (TTM) is -1.89, based on as-reported figures from SEC (XBRL) filings.
What is IN8bio, Inc. Common Stock's Net Debt?
IN8bio, Inc. Common Stock's Net Debt is -$18.0M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Severance and related charges——
Total operating expenses
Interest income
Loss from operations
Net loss
Net loss per share - basic
Net loss per share - diluted